What are the side effects of immunoglobulin therapy (intravenous immunoglobulin [IVIG] or subcutaneous immunoglobulin [SCIG])?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Side Effects of Immunoglobulin Therapy

Immunoglobulin therapy causes side effects ranging from very common mild reactions (occurring in ~80% of patients) to rare but serious life-threatening complications (occurring in <1% of patients), with the severity and type varying significantly between intravenous (IVIG) and subcutaneous (SCIG) routes. 1

Classification by Severity and Timing

Mild Side Effects (Very Common: ~80% of patients)

Local reactions are the predominant side effect, particularly with SCIG:

  • Pain, tenderness, swelling, and erythema at injection site 2
  • Redness, swelling, and itching (most frequent with SCIG) 3
  • These persist hours to 1-2 days after administration 2
  • Important: Local reactions decrease over time - from 37% during first 4 infusions to 16% during last 4 infusions 3

Systemic mild reactions include:

  • Flu-like symptoms: fever, chills, fatigue 1
  • Headache (18.6% in adults) 3
  • Myalgia and malaise 2, 4
  • These are self-limiting and can be reduced by slowing infusion rate 1

Moderate Side Effects (Common: ~6% of patients)

These occur during or shortly after infusion:

  • Joint pain, diarrhea, dizziness 2
  • Dermatological effects: eczema, papules, urticaria 1
  • Back and abdominal pain, nausea, vomiting (within first 10 minutes) 2
  • Drowsiness, pruritis, rash, perspiration, vasodilation 2
  • Skin lesions typically occur within 2 weeks and can be managed with corticosteroids 1

Severe Side Effects (Rare: ~1% of patients)

Immediate severe reactions:

  • Anaphylaxis and anaphylactoid reactions - symptoms include flushing, facial swelling, dyspnea, cyanosis, anxiety, hypotension, loss of consciousness, and potentially death 2

    • Occur within seconds to hours after infusion 2
    • Management: Immediate discontinuation + epinephrine + oxygen + antihistamines + IV steroids + cardiorespiratory support 2
  • Hypotension and arrhythmias (including supraventricular tachycardia) 1

  • Transfusion-Related Acute Lung Injury (TRALI) - manifests within 6 hours with pulmonary edema and acute respiratory distress; has high mortality 1

Delayed severe reactions (<1% of patients):

  • Aseptic Meningitis Syndrome (AMS) 2

    • Begins within hours to 2 days after treatment
    • More frequent with high-dose therapy (2 g/kg body weight)
    • Characterized by: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, vomiting
    • Discontinuation results in remission within days without sequelae 2
  • Renal dysfunction including acute renal failure 2, 5

    • Can result from transient ischemia or acute tubular obstruction 1
  • Thrombosis - veins, intracranial vessels, arteries leading to stroke or myocardial infarction 1

    • Critical finding: SCIG has significantly lower thromboembolic risk (0.14 per 100 patient-years) compared to IVIG (1.8 per 100 patient-years) 6
  • Hemolysis 5, 4

    • Especially after high-dose IVIG infusions
    • Rare in replacement therapy 7
  • Neurological: posterior reversible encephalopathy syndrome 1

  • Hematological: neutropenia 1

Route-Specific Differences

IVIG has higher rates of:

  • Systemic adverse reactions 1
  • Thromboembolic complications 6
  • Severe reactions requiring hospitalization 4

SCIG has:

  • Predominantly mild local reactions (73% of patients experience local reactions) 3
  • Fewer systemic reactions 1, 8
  • Enhanced safety profile - only 3 thromboembolic events documented in SCIg cohorts, all in patients with pre-existing prothrombotic risk factors 6
  • Improved treatment satisfaction 8

Risk Factors for Serious Complications

High-risk patients include those with:

  • Multiple cardiovascular risk factors 9
  • Pre-existing renal failure 9
  • Elderly age 9
  • Selective IgA deficiency with anti-IgA antibodies (risk of anaphylaxis) 2
  • Paraproteins and cardiovascular disease (increased thrombosis risk) 7

Prevention Strategies

To minimize adverse effects:

  1. Infusion rate management: Slow infusion rate for mild reactions 1

  2. Premedication (only for selected high-risk patients, not routine):

    • Corticosteroids (100mg hydrocortisone or 15mg oral prednisolone) 1
    • Acetaminophen 2
    • Important: Premedication significantly reduces side effect rates 10
  3. Dose adjustment: Reduce from standard 1g/kg to 0.4g/kg if reactions occur 1

  4. Product switching: Different IVIG products contain varying concentrations of IgA, sugars, amino acids, and sodium 1

  5. Route switching: Consider SCIG for patients with recurrent IVIG reactions 4

  6. Patient monitoring: Most reactions occur within first 6 hours (75.2% are early reactions) 10

Special Considerations

Infectious agent transmission risk: Although stringent controls are applied, the potential for transmission of viruses and theoretically CJD/vCJD agents cannot be totally excluded 2, 5

Pregnancy and lactation: Safety data limited; use only if clearly needed 2

Vaccine interference: May interfere with live virus vaccines (measles, mumps, rubella, varicella) 5, 3

Related Questions

How should a patient with a 2 g/dL IgG paraprotein and immune paresis be evaluated and managed?
What is the incidence of severe headache after Intravenous Immunoglobulin (IVIG) therapy?
Should the second day of Intravenous Immunoglobulin (IVIG) infusion be delayed if the patient develops a fever?
Do the immunoglobulin levels (IgM 223 mg/dL, IgA 320 mg/dL, IgG 1,393 mg/dL) indicate a normal immunoglobulin profile?
What premedications are recommended for patients receiving Intravenous Immunoglobulin (IVIG)?
For a patient already receiving the maximum dose of their current inflammatory bowel disease therapy, which next medication is most likely to be effective and has the lowest risk of loss of response?
What intravenous antibiotic can be used as an equivalent to oral Macrobid (nitrofurantoin) for treating uncomplicated urinary tract infection?
What is the recommended dosing regimen and duration for acyclovir suppressive therapy in patients with frequent recurrent genital herpes, including adjustments for renal impairment?
What is the next step in managing a 67‑year‑old chronic dialysis patient on amitriptyline who became psychotic and combative, received 250 mg intramuscular ketamine, is now asleep with a normal head CT, normal routine labs except markedly elevated serum creatinine, and is at a hospital without dialysis capability?
What antimicrobial regimen should be used to treat a carbapenem‑resistant Klebsiella pneumoniae infection and a concurrent Enterococcus faecalis infection?
Can you provide a SOAP note with appropriate CPT and ICD‑10 codes for a 44‑year‑old female elementary school teacher presenting with possible acute conjunctivitis (pink eye), a history of hypertension and depression, no known drug allergies, and red eyes with drainage and crusting?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.